Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 686

1.

Prostate-specific antigen cutoff of 2.6 ng/mL for prostate cancer screening is associated with favorable pathologic tumor features.

Krumholtz JS, Carvalhal GF, Ramos CG, Smith DS, Thorson P, Yan Y, Humphrey PA, Roehl KA, Catalona WJ.

Urology. 2002 Sep;60(3):469-73; discussion 473-4.

PMID:
12350486
2.
4.
5.
6.

Standard versus age-specific prostate specific antigen reference ranges among men with clinically localized prostate cancer: A pathological analysis.

Partin AW, Criley SR, Subong EN, Zincke H, Walsh PC, Oesterling JE.

J Urol. 1996 Apr;155(4):1336-9.

PMID:
8632568
7.
9.

Prostate-specific antigen-based early detection of prostate cancer--validation of screening without rectal examination.

Schröder FH, Roobol-Bouts M, Vis AN, van der Kwast T, Kranse R.

Urology. 2001 Jan;57(1):83-90.

PMID:
11164149
10.
11.

Histopathological findings in extended prostate biopsy with PSA < or = 4 ng/mL.

Leite KR, Srougi M, Dall'Oglio MF, Sanudo A, Camara-Lopes LH.

Int Braz J Urol. 2008 May-Jun;34(3):283-90; discussion 290-2.

12.

Prognostic significance of prostate-specific antigen in stage T1c prostate cancer treated by radical prostatectomy.

Cookson MS, Fleshner NE, Soloway SM, Fair WR.

Urology. 1997 Jun;49(6):887-93.

PMID:
9187696
13.

Early detection of prostate cancer with low PSA cut-off values leads to significant stage migration in radical prostatectomy specimens.

Berger AP, Spranger R, Kofler K, Steiner H, Bartsch G, Horninger W.

Prostate. 2003 Oct 1;57(2):93-8.

PMID:
12949932
14.

Free prostate-specific antigen improves prostate cancer detection in a high-risk population of men with a normal total PSA and digitalrectal examination.

Uzzo RG, Pinover WH, Horwitz EM, Parlanti A, Mazzoni S, Raysor S, Mirchandani I, Greenberg RE, Pollack A, Hanks GE, Watkins-Bruner D.

Urology. 2003 Apr;61(4):754-9.

PMID:
12670560
15.
16.

Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings.

Epstein JI, Chan DW, Sokoll LJ, Walsh PC, Cox JL, Rittenhouse H, Wolfert R, Carter HB.

J Urol. 1998 Dec;160(6 Pt 2):2407-11. Review.

PMID:
9817393
18.

Impalpable invisible stage T1c prostate cancer: characteristics and clinical relevance in 100 radical prostatectomy specimens--a different view.

Elgamal AA, Van Poppel HP, Van de Voorde WM, Van Dorpe JA, Oyen RH, Baert LV.

J Urol. 1997 Jan;157(1):244-50.

PMID:
8976263
19.

Substratification of stage T1C prostate cancer based on the probability of biochemical recurrence.

Gretzer MB, Epstein JI, Pound CR, Walsh PC, Partin AW.

Urology. 2002 Dec;60(6):1034-9.

PMID:
12475665
20.

African-American men with nonpalpable prostate cancer exhibit greater tumor volume than matched white men.

Sanchez-Ortiz RF, Troncoso P, Babaian RJ, Lloreta J, Johnston DA, Pettaway CA.

Cancer. 2006 Jul 1;107(1):75-82.

Items per page

Supplemental Content

Write to the Help Desk